ARTICLE | Clinical News

Enzon, Santaris preclinical data

December 6, 2010 8:00 AM UTC

In mouse xenograft models of prostate cancer, EZN-4176 demonstrated comparable tumor growth inhibition to that of both MDV3100 and Casodex bicalutamide. The androgen receptor locked nucleic acid (LNA) antisense oligonucleotide (LNA-ON) was developed using LNA technology from Santaris (see BioCentury, July 31, 2006). Data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Berlin. ...